UBS Group Issues Pessimistic Forecast for Jasper Therapeutics (NASDAQ:JSPR) Stock Price

Jasper Therapeutics (NASDAQ:JSPR) had its target price lowered by research analysts at UBS Group from $29.00 to $25.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock.

JSPR has been the subject of several other reports. HC Wainwright lowered their price target on Jasper Therapeutics from $40.00 to $20.00 and set a “buy” rating for the company in a report on Monday, July 7th. Royal Bank Of Canada downgraded shares of Jasper Therapeutics from an “outperform” rating to a “sector perform” rating and set a $5.00 target price on the stock. in a report on Tuesday, July 8th. William Blair reaffirmed a “market perform” rating on shares of Jasper Therapeutics in a research note on Monday, July 7th. Cantor Fitzgerald cut shares of Jasper Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, July 7th. Finally, Evercore ISI dropped their price target on Jasper Therapeutics from $50.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.75.

Jasper Therapeutics Stock Performance

Shares of NASDAQ:JSPR opened at $3.11 on Friday. The company has a 50 day moving average price of $4.16 and a two-hundred day moving average price of $4.78. The company has a market capitalization of $46.71 million, a PE ratio of -0.52 and a beta of 2.70. Jasper Therapeutics has a 52 week low of $2.27 and a 52 week high of $26.05.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.54). On average, sell-side analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Institutional Trading of Jasper Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. increased its position in shares of Jasper Therapeutics by 755.3% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 702,757 shares of the company’s stock worth $3,022,000 after purchasing an additional 620,592 shares during the last quarter. Boxer Capital Management LLC acquired a new position in Jasper Therapeutics during the fourth quarter worth $7,483,000. Integral Health Asset Management LLC increased its holdings in Jasper Therapeutics by 85.7% during the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $13,897,000 after buying an additional 300,000 shares during the last quarter. Braidwell LP raised its position in Jasper Therapeutics by 47.9% during the fourth quarter. Braidwell LP now owns 714,658 shares of the company’s stock worth $15,279,000 after acquiring an additional 231,358 shares in the last quarter. Finally, Soleus Capital Management L.P. lifted its stake in Jasper Therapeutics by 11.2% in the fourth quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company’s stock valued at $31,951,000 after acquiring an additional 150,755 shares during the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.